About Us

Our Story

Clinical & Regulatory Confidence

National Medical Insurance Coverage

Endorsed by Ping An Insurance (China)

NMPA Approval

ISO 13485 Quality Management

Global Regulatory Pathway

Liansheng Medtech is a Shanghai‑based, exclusive global distributor and the single point of contact for all overseas hospitals, distributors, and healthcare partners of the HY2900 HIFU system.

The HY2900 is developed and manufactured by Wuxi Haiying Medical Technology Co., Ltd (无锡海鹰医疗科技股份有限公司), a specialist in focused ultrasound technology. The facility operates under strict NMPA quality standards and holds ISO 13485 certification — the internationally recognized quality management standard for medical device manufacturers.

As the only authorized international trade partner to Wuxi Haiying, Liansheng Medtech handles all export operations and provides direct support to international buyers seeking access to the HY2900 system.

Liansheng Medtech is partly owned by Chance Non-invasive (辰时无创) — China's first dedicated operator of HIFU-based non-invasive treatment centers and the country's leading clinical authority in non-invasive gynecological care. Operating 10+ centers across 7 provinces, with 7 further locations launching before 2027, Chance Non-invasive has established a replicable, full-cycle care model encompassing screening, treatment, and long-term follow-up for uterine fibroids, adenomyosis, and related gynecological indications.

Beyond its physical network, Chance Non-invasive has also built a proprietary AI-enabled platform for uterine fibroids, adenomyosis, and other gynecological indications — connecting clinical data, physician systems, and operational infrastructure into one standardized, fully digital care model.

Through this partnership, Liansheng Medtech's international clients gain access not only to the HY2900 device, but to Chance Non-invasive's clinical expertise, real-world case data, and operational standards — now accessible to international markets for the first time.

For international healthcare institutions, this means access to a clinically proven, regulatory-approved, and operationally supported non-invasive treatment platform — ready for deployment.

The HY2900 HIFU system is included in China’s National Medical Insurance (NHSA) reimbursement framework for uterine fibroid treatment, reflecting recognized reimbursement support within China’s public healthcare system and helping broaden patient access to non-invasive therapy..

The HY2900 system is formally endorsed by Ping An Insurance, one of China's largest insurance groups. Under this endorsement, patients who undergo treatment at a Chance Non-invasive center are eligible for full reimbursement in the event of an ineffective treatment outcome. This insurance-backed guarantee reflects the clinical confidence in the technology and provides healthcare institutions with an additional risk assurance framework when adopting the HY2900 system.

The HY2900 HIFU system is approved in China as a Class III medical device by the National Medical Products Administration (NMPA, formerly CFDA). Registration No.: 国械注准20153181165.This approval reflects compliance with one of China’s most stringent medical device regulatory pathways.

The manufacturing and quality framework supporting the HY2900 system aligns with ISO 13485, the internationally recognized quality management standard for medical devices, which is designed to help ensure consistent product quality and regulatory compliance across the device lifecycle

Liansheng Medtech and Chance Non-invasive is actively supporting the international regulatory certification process for the HY2900 system. FDA (United States) and CE (European Union) certifications are currently in progress, with approval anticipated in 2027. Upon certification, the HY2900 will be fully cleared for clinical deployment across North American and European markets. Healthcare institutions interested in early partnership access are encouraged to contact us directly.